Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
ATTO · Why this verdict
Why Attovia Therapeutics (ATTO) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Attovia is a pre-revenue speculative biotech with 140.4% upside to the analyst target and positive news sentiment, but quality is below the floor (3.0), earnings arrive in 3 days, and insiders have sold heavily.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality scores 3.0/10, below the 4.0 floor, with zero gross and net margins, an operating margin of -39.6% and a Piotroski F-Score of 4.4. Bear case | The quality score rises above 4.0 as revenue begins and margins improve from -39.6%. | Tripped→Stable |
| CounterMargin and quality scores are naturally poor for a clinical-stage biotech, so they say little about the pipeline's value. | ||
The $36.71 analyst target sits 140.4% above the $15.27 price against 15.0% downside, giving a reward-to-risk of 9.36 and an analyst-upside reading of 176%. Targets | Price moves toward the analyst target over ~12 months as clinical and financial milestones are met. | →Stable |
| CounterOnly 5 analysts cover the stock, and a biotech target depends on binary clinical outcomes; the stock is already 46% off its 52-week high, so the market may be pricing in risk the target ignores. | ||
News sentiment is strongly positive at +0.85 and the sentiment score is 8.7/10, with institutions accumulating shares. Sentiment breakdown | Positive news flow continues and sentiment stays above 7.0 through the next two quarters. | ↑Improving |
| CounterThe sentiment reading rests on only 2 news items (n=2), so it is a thin signal that can reverse on a single negative headline. | ||
Earnings arrive in 3 days after the one reported quarter missed (-$4.88 vs -$4.71 expected), and revenue is just $450K in the latest quarter. Earnings | The November 11, 2026 report shows loss per share at or below the estimate and revenue growing above $450K. | ↑Improving |
| CounterA single prior report offers little guide, and a small miss or cash-burn surprise could hit a speculative stock hard right before the event. | ||
The engine flags material insider selling of 21 sells equal to 1.01% of market cap as one of 2 value-trap signals. Bear case | Insider selling slows to fewer than 5 sales per quarter and does not recur after the lock-up period. | →Stable |
| CounterSelling after an IPO may be routine liquidity for early holders rather than a view on the stock, and the last 90 days show no net insider activity. | ||
Quality scores 3.0/10, below the 4.0 floor, with zero gross and net margins, an operating margin of -39.6% and a Piotroski F-Score of 4.4.
Tripped→StableBear case
- Expectation
- The quality score rises above 4.0 as revenue begins and margins improve from -39.6%.
CounterMargin and quality scores are naturally poor for a clinical-stage biotech, so they say little about the pipeline's value.
The $36.71 analyst target sits 140.4% above the $15.27 price against 15.0% downside, giving a reward-to-risk of 9.36 and an analyst-upside reading of 176%.
→StableTargets
- Expectation
- Price moves toward the analyst target over ~12 months as clinical and financial milestones are met.
CounterOnly 5 analysts cover the stock, and a biotech target depends on binary clinical outcomes; the stock is already 46% off its 52-week high, so the market may be pricing in risk the target ignores.
News sentiment is strongly positive at +0.85 and the sentiment score is 8.7/10, with institutions accumulating shares.
↑ImprovingSentiment breakdown
- Expectation
- Positive news flow continues and sentiment stays above 7.0 through the next two quarters.
CounterThe sentiment reading rests on only 2 news items (n=2), so it is a thin signal that can reverse on a single negative headline.
Earnings arrive in 3 days after the one reported quarter missed (-$4.88 vs -$4.71 expected), and revenue is just $450K in the latest quarter.
↑ImprovingEarnings
- Expectation
- The November 11, 2026 report shows loss per share at or below the estimate and revenue growing above $450K.
CounterA single prior report offers little guide, and a small miss or cash-burn surprise could hit a speculative stock hard right before the event.
The engine flags material insider selling of 21 sells equal to 1.01% of market cap as one of 2 value-trap signals.
→StableBear case
- Expectation
- Insider selling slows to fewer than 5 sales per quarter and does not recur after the lock-up period.
CounterSelling after an IPO may be routine liquidity for early holders rather than a view on the stock, and the last 90 days show no net insider activity.
Per-dimension breakdown
Quality
3.0/10data confidence 71%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.7 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 5.5 |
| Volume | 0.9 |
- ▸Volume accumulation (rising OBV)
Sentiment
8.7/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 9.0 |
| Analyst rating | 7.3 |
| Price target | 10.0 |
- ▸LLM news sentiment: +0.80 (n=2)
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 176%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
2.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.8 |
| support resistance | 4.0 |
| 52w position | 0.9 |
Risk (lower is worse)
5.9/10data confidence 60%| Component | Sub-score |
|---|---|
| days to cover | 7.8 |
| volatility | 0.0 |
| debt equity | 9.8 |
Catalyst
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.7 |
| news activity | 6.0 |
- ▸Earnings in 3 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:6.0>=5.5
- ASYMMETRY:9.4>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- EARNINGS_PROXIMITY:3d<=7d
Warning (0)
none
Reward-to-Risk
9.36
Upside
+140.4%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.7B) below institutional reach
SuitabilitySpeculative — Drawdown -46% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the EARNINGS_PROXIMITY gate's 3d<=7d outcome against Value at 9.0 and asymmetric R:R of 9.36.
The strongest dimensions are Value at 9.0, Sentiment at 8.7, and Insider at 7.3; the weakest are Technical at 2.6, Quality at 3.0, and Catalyst at 3.3. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 9.36 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Large Analyst Target Upside
Trip ifAnalyst target falls below $20, cutting upside to less than 30% from 140.4%.
- P2Strong News Sentiment
Trip ifNews sentiment falls below +0.20 from the current +0.85.
- P3Weak Quality No ProfitabilityTripped
Trip ifOperating margin falls below -60% from the current -39.6%.
- P4Earnings Binary Event
Trip ifLoss per share exceeds $5.50 in the November 2026 report, versus $4.88 last time.
- P5Material Insider Selling
Trip ifInsider selling exceeds 2% of market cap over any 90-day window, from the current 1.01%.